Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003.
Patrick-Miller
Linda J
LJ
Department of Psychiatry, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, USA. patmiller@umdnj.edu
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000523:psychology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D006304:Health Status; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D011799:Quinazolines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib